U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

First Page		Document Content
Medicine Maraviroc Center for Drug Evaluation and Research Antiretroviral drug Pfizer CCR5 New Drug Application Zidovudine CCR5 receptor antagonist Food and Drug Administration Chemistry Pharmaceutical sciences		U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 50,74 KB Share Document on Facebook

	PDF Document DocID: 17saC - View Document
	2011 Bull, R.A., J. Hyde, J. M. Mackenzie, G.S. Hansman, T. Oka, N. Takeda and P.A. White[removed]Comparison of the replication properties of murine and human calicivirus RNA-dependent RNA polymerases. Virus Genes. 42:16- DocID: 11sCt - View Document
	Publications 2013 Mark Gorrell Journal Article Diabetes and Non-alcoholic Fatty Liver Disease – A Pathogenic Duo’ Williams, KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM, Endocrine Reviews 2013 Feb;34(1):[removed]B DocID: 11pY5 - View Document
	2010 Bull, R. A., J-S. Eden, W. D. Rawlinson and P. A. White[removed]Rapid Evolution of Pandemic Noroviruses of the GII.4 lineage. PLoS Pathogens. 6: e1000831. Gorry, P.R., A. Ellett, and S.R. Lewin[removed]Maraviroc. I DocID: 10prU - View Document
	Consultation Decision Analytic Protocol to guide the assessment of a pathology test to determine if a patient has been infected with CCR5 tropic HIV-1 for access to maraviroc DocID: VMeV - View Document